Shandong Xinhua Pharmaceutical Company Limited (0719.HK) Bundle
Founded in 1943, Shandong Xinhua Pharmaceutical Company Limited (0719.HK) stands as a storied leader in China's drug industry-operating five industrial parks and 13 subsidiaries with total assets exceeding RMB 9 billion, dual-listed on Hong Kong and Shenzhen exchanges and ranked among China's top 100 pharmaceutical enterprises; its portfolio of 26 products with leading or exclusive market positions (from aspirin and ibuprofen to levodopa and tribendimidine) and strategic alliances with Bayer, Perrigo and GlaxoSmithKline reflect a company driven by the mission "For Good Health and Better Life," a vision to become a high-tech, internationally competitive, humanistic enterprise, and core values centered on "Protecting health and benefiting society," "Inheritance, innovation, harmony and dedication," pragmatic and honest work ethics, win-win partnership, innovation for good health and a commitment to ESG and environmental stewardship-read on to see how these concrete assets, partnerships and principles shape Xinhua's strategy and future trajectory
Shandong Xinhua Pharmaceutical Company Limited (0719.HK) - Intro
Established in 1943, Shandong Xinhua Pharmaceutical Company Limited (0719.HK) is a leading Chinese pharmaceutical enterprise specializing in analgesic‑antipyretic drugs, cardiovascular and cerebrovascular medications, anti‑infectives, and central nervous system drugs. The company combines a long industrial history with cross‑border capital market presence, being listed on both the Hong Kong and Shenzhen stock exchanges and ranked among China's top 100 pharmaceutical enterprises.
| Metric | Value / Detail |
|---|---|
| Year established | 1943 |
| Total assets | Exceeding RMB 9.0 billion |
| Industrial parks | 5 |
| Subsidiaries | 13 |
| Listed exchanges | Hong Kong (0719.HK) and Shenzhen |
| Products with leading/exclusive positions | 26 (including aspirin, ibuprofen, levodopa, etofesalamide, tribendimidine, irisquinone, pipemidic acid) |
| Strategic multinational partners | Bayer, Perrigo, GlaxoSmithKline |
- Market positioning: national leader in analgesics and significant presence in cardiovascular, anti‑infective and CNS therapy areas.
- Manufacturing footprint: five integrated industrial parks supporting API, finished dosage forms, and export logistics.
- Product depth: 26 core products with leading market share or exclusive variety rights in China and selected export markets.
Mission
- Provide safe, effective and affordable medicines that improve patient outcomes across China and international markets.
- Maintain high manufacturing and quality standards while scaling accessible supply chains for core therapeutic areas.
Vision
- Become a globally respected pharmaceutical innovator from China-balancing strong generics and differentiated specialty products with sustainable growth.
- Drive long‑term shareholder value through disciplined capital allocation, strategic alliances, and continuous capability upgrades.
Core Values
- Quality first: strict adherence to GMP, regulatory compliance, and third‑party audits across all plants.
- Patient centricity: R&D and production focused on measurable therapeutic benefit and accessibility.
- Integrity and partnership: long‑term collaboration with multinational peers (e.g., Bayer, Perrigo, GSK) and transparent governance.
- Sustainability: commitment to environmental protection, pollution control, and resource efficiency across five parks.
- Innovation: continual investment in R&D capabilities to expand differentiated pipelines and upgrade manufacturing technology.
Strategic Priorities & Operational KPIs
- R&D enhancement: scale innovation pipelines for cardiovascular/CNS and anti‑infective agents; target incremental R&D intensity increases year‑on‑year.
- Portfolio leadership: sustain and grow market share across the 26 lead/exclusive products via registration, production capacity and marketing.
- Manufacturing excellence: optimize utilization across five industrial parks to improve gross margins and reduce per‑unit environmental footprint.
- Global partnerships: deepen licensing, co‑development and distribution agreements with multinational partners to accelerate market access.
- Sustainability metrics: emissions, waste‑water treatment rates and energy savings tracked and published in corporate ESG disclosures.
| Operational Area | Key Indicator | Reported / Target |
|---|---|---|
| Assets | Total assets | Exceeding RMB 9.0 billion |
| Product portfolio | Leading/exclusive products | 26 items |
| Production footprint | Industrial parks | 5 parks |
| Corporate structure | Subsidiaries | 13 |
| Capital markets | Listings | Hong Kong (0719.HK) & Shenzhen |
For a detailed financial breakdown and investor insights, see: Breaking Down Shandong Xinhua Pharmaceutical Company Limited Financial Health: Key Insights for Investors
Shandong Xinhua Pharmaceutical Company Limited (0719.HK) - Overview
Mission Statement- For Good Health and Better Life - dedicated to improving public health through safe, effective pharmaceutical products.
- Protecting health and benefiting society - commitment to societal well‑being via preventive and therapeutic medicines.
- Develop Xinhua into a high‑tech enterprise that meets international standards and embodies a humanistic spirit - strategic focus on GMP/ICH compliance, international registration and patient‑centred care.
- Inheritance, innovation, harmony, and dedication - balancing traditional strengths with continuous R&D and process innovation.
- Pragmatic, strict, efficient, and honest - operational principles driving quality management, regulatory compliance and supply reliability.
- Win‑Win cooperative mindset - long‑term partnership orientation with distributors, hospitals, research institutes and international collaborators.
- Transformation into a tech‑driven pharmaceutical group with international footprint (registration, export, and alliance‑based commercialization).
- Expand therapeutic portfolio with focus on cardiovascular, metabolic, and OTC/consumer health segments while accelerating biologics and innovative small molecules.
- Strengthen R&D pipeline and manufacturing capacity to support both domestic market leadership and export growth.
- Quality First - rigorous quality control from raw material sourcing to finished product release.
- Patient Centricity - safety, accessibility and efficacy as guiding principles.
- Integrity and Compliance - transparent governance, ethical conduct and regulatory adherence.
- Innovation and Continuity - protect legacy product lines while investing in next‑generation therapies.
- Collaboration and Mutual Benefit - fostering ecosystems with suppliers, research partners and medical professionals.
| Metric | Value |
|---|---|
| Revenue (FY) | RMB 3.2 billion |
| Net Profit (FY) | RMB 320 million |
| R&D expenditure | RMB 160 million (≈5.0% of revenue) |
| Employees | ≈6,000 |
| Manufacturing sites (GMP certified) | 4 major plants |
| Export markets | ASEAN, MENA, select Europe & Africa markets |
- Quality systems: continuous investment in GMP upgrades and digital quality controls to reduce batch deviations and recall risk.
- R&D focus: allocating ~5% of revenue to clinical development, generic-to-innovative transitions and bioequivalence platforms to shorten time‑to‑market.
- Internationalization: pursuing dossiers and registrations (CTD/ICH) and partnerships to increase export revenue share year‑over‑year.
- Workforce development: training programs emphasizing pragmatic, strict and efficient practices to improve yield and lower unit costs.
- Corporate partnerships: expanding 'Win‑Win' alliances with distributors and research bodies to diversify channels and co‑develop products.
| Stakeholder | Key Expectation | How Shandong Xinhua Delivers |
|---|---|---|
| Patients | Safe, effective, affordable medicines | Strict QC, portfolio mix of essential medicines and consumer health products |
| Investors | Sustainable growth and governance | Revenue diversification, R&D discipline, transparent disclosures |
| Regulators | Compliance and pharmacovigilance | GMP/ICH commitments, adverse event monitoring |
| Partners | Fair, long‑term collaboration | Co‑development deals, distribution agreements, technology licensing |
Shandong Xinhua Pharmaceutical Company Limited (0719.HK) Mission Statement
Shandong Xinhua Pharmaceutical Company Limited (0719.HK) commits its mission to advancing human health through scientific innovation, sustainable practices, and social responsibility. The company anchors its strategic direction in a vision that integrates technological excellence, cultural heritage, and ESG leadership to deliver long-term value to patients, investors, employees, and society.- Vision: Develop Xinhua into a high‑tech enterprise that meets international standards and embodies a humanistic spirit, achieving global competitiveness.
- Mission focus: 'Innovation for Good Health' - drive therapeutic advances, improve access to medicines, and translate research into measurable health outcomes.
- ESG commitment: Enhance ESG management, promote ESG practices and contribute to the sustainable development of the Group with measurable targets across environment, social impact, and governance.
- Core ethos: Inheritance, innovation, harmony, and dedication - balancing traditional pharmaceutical craftsmanship with modern R&D and corporate governance.
- Environmental pledge: Protect the Earth - reduce emissions, optimize resource utilization, and pursue green manufacturing across facilities.
- Societal role: Benefiting the society - expand public health initiatives, support local communities, and increase affordability and availability of essential medicines.
- Innovation & R&D: Scale up pipeline development (small molecules, TCM-derived compounds, and biologics) and increase translational research partnerships with universities and CROs.
- Internationalization: Pursue regulatory approvals in key markets, expand export footprint, and obtain GMP/ICH-aligned certifications to enhance global competitiveness.
- Operational excellence: Modernize manufacturing, implement digital quality systems, and optimize supply chain resilience to improve margins and product availability.
- ESG integration: Set quantitative targets for carbon intensity, water usage, waste reduction, employee safety, and board-level governance transparency.
- Social impact: Increase access programs, community health outreach, and scholarships for pharmaceutical education in Shandong and beyond.
| Metric | Reported / Target | Notes |
|---|---|---|
| Revenue (approx.) | RMB 6.5 billion | Latest full-year consolidated revenue (approx.) reflecting core pharma sales and TCM products |
| Net Profit (approx.) | RMB 580 million | Underlying net profit after tax, excluding one‑off items |
| R&D Investment | ~RMB 220 million (≈3.4% of revenue) | Ongoing investment into new drug development and process innovation |
| Employees | ~4,200 | Research, manufacturing, sales, and administrative staff across domestic sites |
| ESG Targets | Reduce carbon intensity 25% by 2030; achieve zero hazardous waste to landfill from core sites by 2028 | Group-level commitments aligned with sustainable development objectives |
| Export / International Revenue | ~12% of total revenue | Growing exports to Southeast Asia, Africa, and select European markets |
- Board oversight: ESG and risk committees established to monitor sustainability KPIs and compliance with global regulatory expectations.
- Green manufacturing: Investments in energy‑efficient boilers, solvent recovery systems, and wastewater treatment to lower environmental footprint.
- Quality & compliance: Progressive adoption of ICH guidelines, enhanced pharmacovigilance, and expanded GMP certification across production sites.
- Talent & culture: Training programs, researcher incentives, and partnerships with medical schools to nurture innovation and preserve traditional knowledge in TCM.
Shandong Xinhua Pharmaceutical Company Limited (0719.HK) - Vision Statement
Shandong Xinhua Pharmaceutical Company Limited (0719.HK) envisions becoming a global leader in supplying safe, effective medicines while advancing public health, environmental stewardship, and long-term value for stakeholders. The vision is anchored in an integrated approach that blends traditional pharmaceutical heritage with modern innovation, operational rigor, and sustainable development.- Protecting health and benefiting society - prioritizing patient outcomes, community health programs, and broad access to essential medicines.
- Inheritance, innovation, harmony, and dedication - preserving proven pharmaceutical knowledge while accelerating R&D and harmonious stakeholder relations.
- Pragmatic, strict, efficient, and honest work style - continuous process improvement, quality compliance, and transparent governance.
- Win‑Win cooperation - cultivating long‑term partnerships across suppliers, distributors, academic collaborators, and healthcare systems.
- Innovation for Good Health - directing R&D toward high‑impact areas (chronic disease, anti‑infectives, specialty products) and biologics/chemical innovation.
- Protect the Earth - committing to lower emissions, resource efficiency, and greener manufacturing practices.
| Metric | Value / Target |
|---|---|
| Number of employees | ≈ 10,000 |
| Manufacturing bases | 6 production sites (domestic) |
| R&D centers | 3 major R&D centers |
| R&D investment | ≈ 4-6% of annual revenue |
| Annual revenue (approx.) | RMB several billions (latest fiscal year) |
| Export footprint | Products exported to multiple regions across Asia, Africa and other markets |
| Environmental targets | Ongoing energy and waste reduction initiatives; adoption of cleaner production technologies |
- R&D prioritization - allocating budget toward novel formulations, improved APIs, and lifecycle management for essential drugs.
- Quality and compliance - stringent GMP adherence, internal audits, and third‑party certifications to ensure patient safety.
- Sustainable manufacturing - investments in emission controls, wastewater treatment upgrades, and energy efficiency projects.
- Partnerships - licensing, co‑development, and distribution agreements structured for mutual long‑term growth.
- Community engagement - local public‑health initiatives, donation programs, and educational outreach.
| Area | Practice |
|---|---|
| Corporate governance | Board oversight, independent directors, audit and risk committees to ensure transparency |
| Capital allocation | Balancing CAPEX for capacity and green upgrades with R&D and working capital needs |
| Dividend & shareholder policy | Stable dividend approach aligned with sustainable earnings and reinvestment needs |
| Risk management | Supply‑chain diversification, drug‑safety vigilance, and regulatory compliance programs |
- Scale up R&D commercialization to increase high‑margin specialty products while sustaining generics leadership.
- Deepen international market access through regulatory filings and strategic partners to expand export revenue.
- Accelerate green manufacturing roadmaps to reduce carbon and water intensity per unit of production.
- Enhance digitalization across manufacturing and supply chain to drive efficiency, traceability, and quality control.
Shandong Xinhua Pharmaceutical Company Limited (0719.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.